It certainly reads well. November indicated they had 2 inhibitors better than omomyc, and i think they indicated they were still only part way through screening for others. I think they suggested previously that they planned to thoroughly investigate all the proprietry inhibitors they identify before selecting nest candidate to put forward, which makes perfect sense. I guess that is the next inflection point.
Am i correct in now assuming that for any given cell type there SHOULD be a best cpp from our libraries that works for that particular cell type and shows endosomal escape as a measurable quantity, and coupled with that there will be an myc inhibitor that will end up always being the same one, ie whichever one we finally select as our best candidate.
It certainly sounds like we are heading towards a one stop shop solution. The wuestion now is how long to narrow down all the potential candidates. Maybe the technology is too good and we have a hard time picking "the one" lol
- Forums
- ASX - By Stock
- PYC
- Ann: Half Yearly Report and Accounts
PYC
pyc therapeutics limited
Add to My Watchlist
0.40%
!
$1.27

Ann: Half Yearly Report and Accounts, page-4
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.27 |
Change
0.005(0.40%) |
Mkt cap ! $740.7M |
Open | High | Low | Value | Volume |
$1.27 | $1.29 | $1.27 | $406.0K | 319.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 13987 | $1.27 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.29 | 1380 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 13987 | 1.265 |
1 | 15000 | 1.260 |
1 | 12000 | 1.255 |
1 | 4000 | 1.225 |
1 | 20000 | 1.220 |
Price($) | Vol. | No. |
---|---|---|
1.290 | 25630 | 2 |
1.295 | 24500 | 1 |
1.300 | 59168 | 4 |
1.325 | 9001 | 1 |
1.330 | 20000 | 2 |
Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
Featured News
PYC (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online